GB2478849A — Improved pharmecutical compositions and methods of delivery
Assigned to Amryt Endo Inc · Expires 2011-09-21 · 15y expired
What this patent protects
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent such as CCK-8, octreotide or aliskiren, at least one salt of a medium chain fatty acid, a hydrophobic (lip…
USPTO Abstract
The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent such as CCK-8, octreotide or aliskiren, at least one salt of a medium chain fatty acid, a hydrophobic (lipophilic) medium and optionally a matrix forming polymer and a bile salt. A surfactant may be included in the suspension. The pharmaceutical compositions may be formulated in a capsule or tablet for oral delivery. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.